Skip to main content
    Back to Blog
    biotechlife scienceshealthcaredrug developmentventure capitalfundraisingFDA

    Biotech Fundraising: What is Different?

    AngelBacked TeamSeptember 18, 20256 min read
    Biotech Fundraising: What is Different?

    Biotech fundraising operates by different rules than software startups. Longer timelines, higher capital requirements, and regulatory complexity create a unique investor landscape. Understanding these differences is critical for life sciences founders.

    How Biotech Differs from Software

    FactorSoftware StartupsBiotech Startups
    Time to Revenue6-18 months5-15 years
    Capital Required$1-20M to profitability$100M-$1B+ to approval
    Failure Rate70-80%90%+ (drug development)
    Exit Timeline5-10 years10-20 years
    Revenue ModelRecurring/transactionalBinary (approval or not)
    Key MilestonesUsers, revenue, growthClinical data, FDA approval

    The Biotech Funding Stages

    Stage 1: Discovery/Platform ($1M-$10M)

    Focus: Validating the science

    • Proof of concept data
    • Target validation
    • Platform development
    • Early IP filing

    Typical investors: Grants, angels, small biotech VCs, academic funds

    Stage 2: Preclinical ($10M-$50M)

    Focus: Preparing for human trials

    • Lead compound optimization
    • IND-enabling studies
    • Manufacturing process development
    • Toxicology studies

    Typical investors: Series A biotech VCs

    Stage 3: Phase 1/2 ($30M-$100M)

    Focus: Early human trials

    • Safety and dosing studies
    • Early efficacy signals
    • Patient enrollment
    • Biomarker development

    Typical investors: Series B investors, crossover funds

    Stage 4: Phase 3 ($100M-$500M+)

    Focus: Pivotal trials for approval

    • Large-scale efficacy trials
    • Regulatory submissions
    • Commercial preparation
    • Manufacturing scale-up

    Typical investors: Crossover funds, public markets, pharma partnerships

    What Biotech Investors Evaluate

    1. Scientific Foundation

    ElementWhat Investors Want
    Mechanism of ActionNovel, validated biology
    Data QualityReproducible, peer-reviewed
    IP PositionBroad, defensible patents
    Platform PotentialMultiple programs possible

    2. Clinical Strategy

    • Regulatory pathway - Clear FDA strategy
    • Indication selection - Appropriate patient population
    • Trial design - Endpoints that will support approval
    • Competitive landscape - Differentiation from alternatives

    3. Team Composition

    Essential roles:

    • Scientific founder - Deep domain expertise
    • Drug development experience - Someone who has done it before
    • Clinical leadership - Trial design and execution
    • Regulatory expertise - FDA navigation

    4. Capital Efficiency

    • Milestone-based funding - Clear use of capital
    • Risk mitigation - Derisking strategy
    • Partnership potential - Pharma interest
    • Alternative paths - Options if trials fail

    Types of Biotech Investors

    Dedicated Life Sciences VCs

    FirmStage FocusNotable
    Third Rock VenturesCompany creationBuilt Moderna
    Flagship PioneeringPlatform creationCreated Moderna
    Atlas VentureSeed/Series ALong track record
    ARCH Venture PartnersEarly stageDeep science focus
    Versant VenturesEarly to growthCompany building

    What they bring:

    • Scientific expertise for diligence
    • Drug development experience
    • Pharma relationships
    • Patient capital

    Crossover Investors

    Funds that invest in both private and public biotech:

    • RA Capital
    • OrbiMed
    • Baker Brothers
    • Perceptive Advisors

    When they invest: Late-stage privates, IPO participation, post-IPO

    Strategic Investors (Pharma)

    Corporate venture arms of pharmaceutical companies:

    • Advantages: Validation, partnership potential, expertise
    • Disadvantages: Potential conflicts, slower decisions, strategic strings

    Government and Foundation Funding

    • NIH grants - SBIR/STTR programs
    • BARDA - Biodefense and pandemic preparedness
    • Disease foundations - Patient advocacy organizations
    • State programs - Life sciences incentives

    Biotech-Specific Deal Structures

    Common Instruments

    StructureWhen UsedKey Terms
    Preferred equityMost roundsLiquidation preference, anti-dilution
    Milestone-based tranchesHigh-risk stagesCapital released on data
    Synthetic biology royaltiesPlatform playsRevenue share on programs
    WarrantsBridge financingUpside participation

    Milestone-Based Funding

    Common in biotech to reduce risk:

    • Tranche 1: Initial capital for key experiment
    • Tranche 2: Released upon positive data
    • Tranche 3: Released upon IND filing

    Founder consideration: Understand dilution implications if milestones are missed.

    Biotech Valuation Drivers

    Key Factors

    1. Clinical data - Positive results dramatically increase value
    2. Stage advancement - Each stage cleared adds value
    3. Market size - Indication potential
    4. Competitive position - First-in-class vs. best-in-class
    5. IP strength - Patent protection duration
    6. Team quality - Execution credibility

    Valuation Benchmarks (2025)

    StageTypical Valuation Range
    Seed/Platform$5M-$30M
    Series A (preclinical)$30M-$100M
    Series B (Phase 1/2)$100M-$400M
    Series C/Pre-IPO$400M-$1B+

    Common Biotech Fundraising Mistakes

    1. Underestimating Capital Needs

    Biotech always takes more money and time than planned. Build buffer into projections.

    2. Wrong Investor Type

    Generalist tech VCs often do not understand biotech timelines and risk profiles.

    3. Ignoring Regulatory Strategy

    FDA pathway should be clear from the start, not an afterthought.

    4. Weak IP Position

    Patent strategy is critical. Engage patent counsel early.

    5. Team Gaps

    Investors want to see drug development experience, not just scientific founders.

    Preparing for Biotech Fundraising

    Materials Needed

    1. Scientific presentation - Mechanism, data, competitive landscape
    2. Development plan - Timeline, milestones, capital needs
    3. Regulatory strategy - FDA pathway, trial design
    4. IP summary - Patent portfolio, freedom to operate
    5. Team bios - Relevant drug development experience
    6. Financial projections - Capital needs by stage

    Building Investor Relationships

    • Start early - 12-18 months before you need capital
    • Scientific conferences - JPM Healthcare, BIO, ASCO
    • Publish data - Peer-reviewed credibility
    • Advisory relationships - Strategic advisors open doors

    Alternative Funding Sources

    Non-Dilutive Capital

    SourceTypical AmountBest For
    NIH SBIR/STTR$250K-$2MEarly research
    BARDA$10M-$500MInfectious disease, biodefense
    Disease foundations$100K-$5MSpecific indications
    State grants$100K-$1MLocal job creation

    Pharma Partnerships

    Structures include:

    • Research collaborations - Funded research programs
    • Option deals - Right to acquire/license
    • Co-development - Shared costs and economics
    • Licensing - Upfront + milestones + royalties

    Key Takeaways

    1. Biotech is a different game - Longer timelines, higher capital, different metrics
    2. Target specialized investors - Generalist VCs often do not fit
    3. Scientific credibility matters - Data and publications build trust
    4. Team experience is critical - Drug development expertise required
    5. Milestone-based thinking - Value created at clinical inflection points
    6. Capital efficiency - Do more with less before each raise

    Resources

    • NIH SBIR/STTR: sbir.nih.gov
    • BIO Convention: bio.org
    • JP Morgan Healthcare Conference: Annual industry gathering
    • Endpoints News: Industry publication
    Share this article

    Find the investors who actually fund companies like yours

    AngelBacked maps thousands of angels and VCs to your stage, sector, and geography, so you pitch the right people first.

    Start free

    Free Tools for Founders

    Biotech Fundraising: What is Different? | AngelBacked